How many clinical trials are there for Immune Thrombocytopenic Purpura?

PlainTrial tracks 4 US clinical trials for Immune Thrombocytopenic Purpura, of which 0 are currently recruiting.

Which interventions appear most often on Immune Thrombocytopenic Purpura trial records?

Fostamatinib Disodium is the most-linked intervention name on Immune Thrombocytopenic Purpura records (2 trial links), followed by Inactivated Trivalent Influenza vaccine. Names are sponsor-reported on ClinicalTrials.gov.

How do I find a recruiting trial for Immune Thrombocytopenic Purpura?

Use the trial list filtered by Recruiting status, or visit the trial finder to search by condition and state. Always discuss with your healthcare provider.

Is this data current?

Data is from ClinicalTrials.gov. Trial status may have changed. Always verify at ClinicalTrials.gov before making participation decisions.

Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov enrollment closed later-stage tilt small index

Immune Thrombocytopenic Purpura: later-stage trial registry

Compiled by PlainTrial · August 8, 2026

A small indexed set (4 trials) with no open enrollment listed right now.

Corpus placement: #4,115 of 28,707 conditions by registered trial count.

Jump to phase mix → How counts are built

4 US clinical trials · none currently recruiting · #4,115 of 28,707 conditions by registered trial count

Immune Thrombocytopenic Purpura: 4 US clinical trials tracked, none currently recruiting.

Immune Thrombocytopenic Purpura is the subject of 4 registered US clinical trials on ClinicalTrials.gov, none currently recruiting. 2 are in Phase 3-4 (later-stage) and 0 in Phase 1-2 (earlier-stage). The most active sponsor is Rigel Pharmaceuticals, running 2 of these trials.

Enrollment posture brief

Registry condition immune-thrombocytopenic-purpura

Volume-matched condition peers

Nearest open-share peer: Accelerated Phase Chronic Myelogenous Leukemia (0% recruiting · 12 trials)

Open-enrollment share among volume-matched conditions near Immune Thrombocytopenic Purpura

Immune Thrombocytopenic Purpura has no open enrollment in this registry pull (4 archived studies). Peers show how other volume-matched labels compare on open share. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Immune Thrombocytopenic Purpura on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

Immune Thrombocytopenic Purpura is recruiting below its size-band peers.

0 of 4 indexed trials (0%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

Indexed trials (enrollment closed)

4 total, page 1 of 1

COMPLETED 200 participants

An Epidemiological Study of Subjects With Immune Thrombocytopenic Purpura to Evaluate the Relationship Between Platelet Counts, Endogenous Thrombopoietin Levels, Endogenous Anti-Thrombopoietin Antibodies, and Selected Autoimmune Markers

National Heart, Lung, and Blood Institute (NHLBI)

NCT00005570

COMPLETED Phase 3 123 participants

Open Label Study of R788 in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP)

Rigel Pharmaceuticals

NCT02077192

COMPLETED Phase 3 74 participants

A Efficacy and Safety Study of Fostamatinib in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP)

Rigel Pharmaceuticals

NCT02076412

COMPLETED NA 10 participants

Vaccine Response After Rituximab for Chronic, Severe Idiopathic Thrombocytopenic Purpura

Neufeld, Ellis J, MD, PhD

NCT01713855

Phase Distribution

Phase	Trial count
Phase 3	2

Top Sponsors

Rigel Pharmaceuticals 2 trials

Neufeld, Ellis J, MD, PhD 1 trials

National Heart, Lung, and Blood Institute (NHLBI) 1 trials

Named interventions

Most-linked intervention names on Immune Thrombocytopenic Purpura records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Fostamatinib Disodium Drug

2 trials

Inactivated Trivalent Influenza vaccine Biological

1 trials

Placebo Drug

1 trials

US sites by state

Facility locations filed on Immune Thrombocytopenic Purpura trials. A trial with sites in several states counts in each.

New York 2 trials

Maryland 2 trials

Ohio 1 trials

North Carolina 1 trials

Massachusetts 1 trials

Indiana 1 trials

Illinois 1 trials

Georgia 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Immune Thrombocytopenic Purpura page

4 registered trials, 0 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

No Immune Thrombocytopenic Purpura trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
Rigel Pharmaceuticals sponsors the most Immune Thrombocytopenic Purpura trials on record, review their full trial history before evaluating a specific study. See Rigel Pharmaceuticals's trials
Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Immune Thrombocytopenic Purpura condition card totals 4 registered trials; most-linked intervention Fostamatinib Disodium; top US site state New York. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.